PureTech Health Stock

PureTech Health Equity

Delisted·Jun 19, 2026

The The Equity of PureTech Health (PRTC.L) as of Aug 4, 2026 is 414.71 M USD. In the previous year, The Equity was 464.07 M USD — a change of -10.64% (lower).

Equity

414.71 MUSD

YoY

-10.64%

Last updated:

In 2026, PureTech Health's equity was 414.71 M USD, a -10.64% increase from the 464.07 M USD equity in the previous year.

Access this data via the Eulerpool API

PureTech Health Stock analysis

What does PureTech Health do? PureTech Health is an innovative company specializing in the development of novel medical therapies and solutions. The company was founded in 2002 by Daphne Zohar and is headquartered in Boston, USA. PureTech Health is listed on the London Stock Exchange and has become one of the leading biotech companies in recent years. The company's business model is based on identifying medical needs and developing new products and therapies to meet those needs. It utilizes cutting-edge technologies to work quickly and effectively. Research and development are closely linked in an iterative process. PureTech Health's main focus is oncology, specifically developing immune-oncology therapies that target the patient's immune system to strengthen their body's defense against cancer cells. The company has also developed an innovative drug discovery system that combines nanotechnology and artificial intelligence. Another focus area for PureTech Health is gastroenterology. The company has developed a novel technology that selectively releases medical substances in the intestine, allowing targeted treatment of gastrointestinal diseases. PureTech Health has also developed a new method for diagnosing colorectal cancer based on the identification of bacteria in feces. In the field of neuropsychiatric disorders, the company has promising research results. It has developed a new technology that enables targeted manipulation of the central nervous system, allowing for the treatment of conditions such as depression, anxiety disorders, and ADHD. To this end, PureTech Health has developed a novel nasal spray that delivers the active ingredients directly to the brain. Biosensing is another area of focus for PureTech Health. The company has developed a novel technology that allows for the measurement of medical parameters such as blood sugar, cholesterol, and blood pressure. The sensors are available in the form of patches or other wearable devices and are easy and convenient to use. This technology is intended to help older people and those with chronic illnesses better monitor their health. Overall, PureTech Health is an innovative biotech company that is constantly seeking novel medical solutions. It operates in various areas and has promising products and therapies in the pipeline. With its close integration of research and development, PureTech Health is able to quickly and flexibly respond to market changes. With strong management and an experienced team, the company is well-positioned for further growth in the coming years. PureTech Health is one of the most popular companies on Eulerpool.

Equity Details

Analyzing PureTech Health's Equity

PureTech Health's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding PureTech Health's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating PureTech Health's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

PureTech Health's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in PureTech Health’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about PureTech Health stock

The Equity of PureTech Health is 414.71 M USD in 2026.

The Equity of PureTech Health changed from 464.07 M USD to 414.71 M USD, representing a -10.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity PureTech Health since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's PureTech Health historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — PureTech Health

All Key Metrics — PureTech Health